Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 15th June 2020

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Zoom.
The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda for September 2020.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Cefazolin 1g & 2g powder for solution for injection/infusion**

Requested by Microbiology for the treatment of infections caused by methicillin-susceptible *Staphylococcus aureus* where flucloxacillin cannot be used. Cefazoline is an unlicensed generic medicine currently being imported from the Netherlands.
Cefazoline will be a second-line treatment option when flucloxacillin cannot be used due to side-effects or intolerance and will provide an alternative option with a similar efficacy to flucloxacillin in the treatment of invasive Methicillin-Susceptible *Staphylococcus aureus* (MSSA) infections and improved patient outcomes.
Outcome: Approved for addition to the Formulary

- **Prasterone 6.5mg Pessary (Intrarosa®)**

Requested by Gynaecology for the management for vulvar and vaginal atrophy in postmenopausal women experiencing moderate to severe symptoms.
Outcome: No presenter attended the meeting.

Ex-panel

- **Aflibercept (Eylea®) 40mg/ml Pre-filled Syringes**

CWFT have been offered Aflibercept PFS at the same contract price as the vials.
The pre-filled syringes require fewer manipulations so reduce the risk of infection/contamination and would be preferred by the nurse and consultants.
The dosing is the same for both products.
Pharmacy have been asked to order either PFS or vials going forward and the preference is to use the PFS.
Will affect CWH site only as there is no Ophthalmology services at WMUH.
Outcome: Approved for addition to the Formulary

- **Vedolizumab (Entyvio®) 108 mg Pre-filled Pen**

This is new formulation is available from 1st June for the maintenance treatment of patients with moderately to severely active Ulcerative Colitis or Crohn's Disease. Patients can switch to SC dosing after receiving the 3 x IV loading doses.
2 trials Visible 1 for UC patients and Visible 2 for patients with Crohn's Disease have shown that the subcutaneous route is as efficacious as intravenous dosing. Subcutaneous dosing allows the patient to administer treatment at home via a pre-filled pen and to receive medication delivered via homecare services.
Homecare delivery allows VAT saving and also release of capacity in infusion units.
The annual cost of SC dosing remains the same as for the IV route.
NICE consider this to be the same treatment and advise that it is covered by the current approvals TA342 & TA352.
Our local commissioners are supportive of the use of the SC formulation.
Outcome: Approved for addition to the Formulary

Removals

- **Duavive® (Conjugated oestrogens 0.45mg & Bazedoxifene 20mg) MR Tablet**

Pfizer have confirmed that Duavive® tablets were initially discontinued in August 2018 however they continued to supply whilst they had stock. Pfizer issued a statement on 21st May 2020 stating that their stocks have now been exhausted and they will not be making any further supplies of Duavive®.
Outcome: Approved for removal from the Formulary

NICE Approved drug applications

- **Nil**

Switches

- **Budesonide foam enemas 2mg/application to replace Prednisolone foam enema 20mg/application**

Proposed switch from Prednisolone foam enemas to Budesonide enemas in line with cost saving initiatives proposed by NWL CCG.
Outcome: Approved switch to the Formulary

Pharmacoeconomic Board requests

- **Tocilizumab for ITU patients**

Approved by Pharmacoeconomic Board on 7th May 2020.
Outcome: Noted

- **Alirocumab for Familial Combined Hyperlipidaemia**

Approved by Pharmacoeconomic Board on 28th May 2020.
Outcome: Noted

Other

- **Venetoclax for AML**

Ventoclax in combination with Azacitidine in a newly diagnosed AML patient Off-label and off-protocol use
Approved by Trust CSG and Pharmacoeconomic Board on 16th April 2020.
Outcome: Noted

4.2 Trust Medicines Policy

- **Updated to Trust Adult IV Administration Guide**
  - Noradrenaline monograph updated Changed because Pharmacy imported an American brand with bitartrate salt and have been using higher conc in covid patients:
  - New Monograph for Natalizumab (Tysabri®)

Approved by Chair's Action on 17th April 2020.
Outcome: Noted

- **Administration of Phyomenadione Injection under Midwife Exemptions**

Midwives are usually not authorised to administer an unlicensed product under Midwives Exemptions.
However, during the Covid Pandemic and due to a shortage of licensed Vitamin K, the official DHSC guidance implies that the unlicensed product can be administered under Midwives Exemptions providing local governance committees are happy to approve.
Approved by Acting Medical Director, Chair TMG and Chief Pharmacist.
Memo circulated for communication.
Outcome: Noted

4.3 Medicines Optimisation

- **Vitamin D and Coronavirus Leaflets**

CWFT, in line with national guidance, have produced a Vitamin D leaflet for patients during the Coronavirus Pandemic.

This leaflet highlights that patients who are staying at home and/or 'shielded' at this time (during summer months) may be more at risk of vitamin D deficiency. Therefore, unless contraindicated, patients should consider buying and taking vitamin D supplements containing 10mcg (400units) of vitamin D.

Pharmacy Department are currently placing a copy of this leaflet in with the discharge prescription for all appropriate patients discharged from the hospital.
Approved via Chair's Action on 01/05/2020.
Outcome: Noted

- **NWL Cost saving initiatives**

Feedback from consultation on cost saving initiatives being proposed by NWL CCG. There has been little progress on this over the last month due to the Covid-19 Pandemic. To be followed-up via the Medicines Optimisation Group.
Outcome: Noted

- **NWL COPD Inhaler Guide**

Version 3 of the NW London COPD Inhaler Guide which now been approved by all the 8 CCGs.
Outcome: Noted

- **Hospital Pharmacy Transformation Plan**

Updated Hospital Pharmacy Transformation Plan is in progress and will be presented at a forthcoming meeting. Update provided on Cerner EPMA roll-out at WMUH Site which is nearing completion.
Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

1 Appraisals published in March 2020

TA625 - Recombinant human parathyroid hormone for treating hypoparathyroidism (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

b) NICE Technology Appraisals published in April 2020

1 Appraisal published in April 2020

TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma
Formulary status / Action
Currently included on the formulary.
Numbers likely to treat at CWH site: 5 patients per year
Numbers likely to treat at WMUH site: 5-6 patients per year

c) NICE Technology Appraisals published in May 2020

2 Appraisals published in May 2020

TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Formulary status / Action
Add to the formulary following receipt of a signed application form from the CW Oncology Team.

TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Formulary status / Action
Currently included on the formulary.
Numbers likely to treat at CWH site: 4 patients per year

Numbers likely to treat at WMUH site: 5 patients per year

d) NICE Highly Specialised Technologies published since last meeting

0 Highly Specialised Technologies published since previous meeting

e) NICE TA Adherence Table 2019-2020
Adherence table that shows CWFT Formulary status for all NICE TAs published in 2019/2020
Outcome: Approved

f) NICE HST Adherence Table 2019-2020
Adherence table that shows CWFT Formulary status for all NICE HSTs published in 2019/2020
Outcome: Approved

4.5 IVIG requests

- **IVIG Issues for January 2020 - WMUH Site**

There were 24 IVIG issues in January 2020, with 11 new requests
Outcome: Noted

- **IVIG Issues for February 2020 - WMUH Site**

There were 14 IVIG issues in February 2020, with 4 new requests
Outcome: Noted

- **IVIG Issues for March 2020 - CWH Site**

There were 12 IVIG issues in March 2020, with 7 new requests
Outcome: Noted

- **IVIG Issues for March 2020 - WMUH Site**

There were 14 IVIG issues in March 2020, with 1 new request
Outcome: Noted

- **IVIG Issues for April 2020 - CWH Site**

There were 4 IVIG issues in April 2020, with 1 new request
Outcome: Noted

- **IVIG Issues for April 2020 - WMUH Site**

There were 14 IVIG issues in April 2020, with 8 new requests
Outcome: Noted

- **IVIG Issues for May 2020 - CWH Site**

There were 6 IVIG issues in May 2020, with 2 new requests
Outcome: Noted

- **IVIG Issues for May 2020 - WMUH Site**

Outcome: Deferred to next month

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q4 2019/20**

Quarterly Controlled Drug Summary Report for Q4 2019/20
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q4 2019/20**

Quarterly CD Accountable Officer Report for Q4 2019/20

Outcome: Noted

- **Trust Patient Safety Group Report - June 2020**

Trust Patient Safety Group Report covering period of March to May 2020
Outcome: Noted

- **Conflicts of Interest form - Pharmacy**

Conflicts of interest form detailing funding of pharmacist to support MS service by Merck Serono
Outcome: Noted

- **MHRA Drug Safety Update - March 2020**

MHRA update for March 2020
Ulipristal Acetate (Esmya®) noted as having its licensed suspended due to serious liver injury.
Action: To be removed from the formulary
Outcome: Noted

- **MHRA Drug Safety Update - April 2020**

MHRA update for April 2020
Action: Update Trust Medicines Policy to reverse changes made in March 2020 to include the following preparations assigned Controlled Drug status in Trust during Coronavirus Pandemic:
Kaletra® (Lopinavir/Ritonavir) 80mg/20mg/ml Liquid
Kaletra® (Lopinavir/Ritonavir) 100mg/25mg Tablets
Kaletra® (Lopinavir/Ritonavir) 200mg/50mg Tablets
Chloroquine 250mg Tablets
Outcome: Noted

- **MHRA Drug Safety Update - May 2020**

MHRA update for May 2020
Outcome: Noted

4.7 Meeting minutes for noting

- **Antibiotic Steering Group - April 2020**

Minutes from Antibiotic Steering Group meeting - April 2020
Outcome: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- **Trust Patient Safety Group Report - March 2020**

5. Any other business
Nil

6. Date of next meeting
Date: 27th July
Time: 8am-9am
Location: Via Zoom
Closing date: 10th July 2020